Good M F, Miller L H, Kumar S, Quakyi I A, Keister D, Adams J H, Moss B, Berzofsky J A, Carter R
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Science. 1988 Oct 28;242(4878):574-7. doi: 10.1126/science.2902690.
Current vaccine development strategies for malaria depend on widespread immunological responsiveness to candidate antigens such as the zygote surface antigens and the sporozoite coat protein, the circumsporozoite (CS) protein. Since immunological responsiveness is controlled mainly by genes mapping within the major histocompatibility complex (MHC), the humoral immune response to the zygote surface antigens and the cytotoxic T lymphocyte (CTL) response to the CS protein were examined in MHC-disparate congenic mouse strains. Only two of six strains responded to the 230-kilodalton zygote surface antigen and another two strains responded to the 48/45-kilodalton surface antigen. From two mouse strains, expressing between them five different class I MHC molecules, there was recognition of only a single CTL epitope from the CS protein, which was from a polymorphic segment of the molecule. The restricted CTL response to this protein parallels the restricted antibody response to this protein observed in humans and mice. These findings suggest that subunit malaria vaccines now being developed may be ineffective.
目前疟疾疫苗的研发策略依赖于对诸如合子表面抗原、子孢子表面蛋白(环子孢子蛋白,CS蛋白)等候选抗原产生广泛的免疫应答。由于免疫应答主要受主要组织相容性复合体(MHC)内定位基因的控制,因此在MHC不同的同源近交系小鼠品系中检测了对合子表面抗原的体液免疫应答以及对CS蛋白的细胞毒性T淋巴细胞(CTL)应答。六个品系中只有两个品系对230千道尔顿的合子表面抗原有应答,另外两个品系对48/45千道尔顿的表面抗原有应答。在表达五种不同I类MHC分子的两个小鼠品系中,仅识别出CS蛋白的一个单一CTL表位,该表位来自该分子的一个多态性片段。对该蛋白的受限CTL应答与在人类和小鼠中观察到的对该蛋白的受限抗体应答相似。这些发现表明,目前正在研发的亚单位疟疾疫苗可能无效。